scholarly journals Exploring Airway Diseases by NMR-Based Metabonomics: A Review of Application to Exhaled Breath Condensate

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Matteo Sofia ◽  
Mauro Maniscalco ◽  
Guglielmo de Laurentiis ◽  
Debora Paris ◽  
Dominique Melck ◽  
...  
Keyword(s):  
Respiratory Diseases ◽  
Exhaled Breath Condensate ◽  
Quantitative Information ◽  
Low Molecular Weight ◽  
Exhaled Breath ◽  
Qualitative And Quantitative ◽  
Airway Diseases ◽  
Breath Condensate ◽  
Potential Use ◽  
Airways Inflammation

There is increasing evidence that biomarkers of exhaled gases or exhaled breath condensate (EBC) may help in detecting abnormalities in respiratory diseases mirroring increased, oxidative stress, airways inflammation and endothelial dysfunction. Beside the traditional techniques to investigate biomarker profiles, “omics” sciences have raised interest in the clinical field as potentially improving disease phenotyping. In particular, metabonomics appears to be an important tool to gain qualitative and quantitative information on low-molecular weight metabolites present in cells, tissues, and fluids. Here, we review the potential use of EBC as a suitable matrix for metabonomic studies using nuclear magnetic resonance (NMR) spectroscopy. By using this approach in airway diseases, it is now possible to separate specific EBC profiles, with implication in disease phenotyping and personalized therapy.

scholarly journals DIAGNOSIS OF RESPIRATORY DISEASES USING THE PROTEOMIC ANALYSIS OF EXHALED BREATH CONDENSATE

2017 ◽  
Vol 27 (2) ◽  
pp. 187-197
Author(s):  
E. Kh. Anaev ◽  
K. Yu. Fedorchenko ◽  
M. E. Kushaeva ◽  
A. M. Ryabokon' ◽  
A. S. Kononikhin ◽  
...  
Keyword(s):  
Proteomic Analysis ◽  
Respiratory Diseases ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Breath Condensate

Clinical metabolomics of exhaled breath condensate in chronic respiratory diseases

2019 ◽  
pp. 121-149 ◽  
Author(s):  
Mauro Maniscalco ◽  
Salvatore Fuschillo ◽  
Debora Paris ◽  
Adele Cutignano ◽  
Alessandro Sanduzzi ◽  
...  
Keyword(s):  
Respiratory Diseases ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Chronic Respiratory Diseases ◽  
Breath Condensate ◽  
Clinical Metabolomics

The pH of the exhaled breath condensate: New method for investigation of inflammatory airway diseases

2007 ◽  
Vol 148 (26) ◽  
pp. 1217-1224 ◽  
Author(s):  
Balázs Szili ◽  
András Bikov ◽  
Márk Kollai ◽  
Ildikó Horváth
Keyword(s):  
Asthma Bronchiale ◽  
Exhaled Breath Condensate ◽  
New Method ◽  
Exhaled Breath ◽  
Airway Diseases ◽  
Breath Condensate

A kilélegzett levegő kondenzálása és a kondenzátum (EBC: Exhaled Breath Condensate) vizsgálata napjainkra egyre szélesebb körben terjed el pulmonológiai kutatásokban. Az eljárás során nem invazív úton nyerhetünk mintát a légutakból úgy, hogy a kilélegzett gázkeveréket egy hűtött kamrán áramoltatjuk át, és a kamra falára lecsapódó párát vizsgáljuk. A minta számos különböző mediátort, biomarkert tartalmaz. Kiemelt jelentőségű a különböző, eddig vizsgált biomarkerek közül a pH. Mérése egyszerű, olcsó és az optimális mérési tartományon belül van. Problémát a pH-érték instabilitása jelent, amit főként a minta CO 2 -koncentrációjának változása okoz. Számos publikáció jelent meg, amelyekben különböző légúti megbetegedésekben vizsgálták a kondenzátum pH-ját. Asthma bronchialéban (különösen akut exacerbatióban), valamint krónikus obstruktív tüdőbetegségben (COPD) savasabbnak találták a kondenzátumot. Szteroidkezelés hatására mindkét betegségben emelkedik a pH. Bronchiectasiában, cisztikus fibrosisban, valamint krónikus köhögésben (asthma bronchiale, gastrooesophagealis reflux, rhinitis chronica, ismeretlen eredet) is savasabbnak találták az EBC-mintákat. A légutak savasodása a különböző kórállapotokban fontos szerepet játszhat a betegségek patomechanizmusában, és az ezt jelző EBC-pH szerepet kaphat a légúti megbetegedések követésében.

scholarly journals Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate

Metabolites ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 847
Author(s):  
Elettra Barberis ◽  
Elia Amede ◽  
Shahzaib Khoso ◽  
Luigi Castello ◽  
Pier Paolo Sainaghi ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Exhaled Breath Condensate ◽  
Diagnostic Tools ◽  
Preventive Strategy ◽  
Noninvasive Diagnosis ◽  
Exhaled Breath ◽  
Tract Damage ◽  
Breath Condensate ◽  
Potential Use ◽  
Potential Biomarkers

Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath’s biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.

Nitrate in exhaled breath condensate of patients with different airway diseases

Nitric Oxide ◽  
2003 ◽  
Vol 8 (1) ◽  
pp. 26-30 ◽  
Author(s):  
Massimo Corradi ◽  
Alberto Pesci ◽  
Romano Casana ◽  
Rossella Alinovi ◽  
Matteo Goldoni ◽  
...  
Keyword(s):  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Airway Diseases ◽  
Breath Condensate

Metabolomics of Exhaled Breath Condensate by Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry: A Methodological Approach

2020 ◽  
Vol 27 (14) ◽  
pp. 2381-2399 ◽  
Author(s):  
Mauro Maniscalco ◽  
Adele Cutignano ◽  
Debora Paris ◽  
Dominique J. Melck ◽  
Antonio Molino ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Respiratory Diseases ◽  
Biomarker Discovery ◽  
Exhaled Breath Condensate ◽  
Resonance Spectroscopy ◽  
Exhaled Breath ◽  
Breath Condensate ◽  
Nuclear Magnetic

: Respiratory diseases present a very high prevalence in the general population, with an increase in morbidity, mortality and health-care expenses worldwide. They are complex and heterogeneous pathologies that may present different pathological facets in different subjects, often with personal evolution. Therefore, there is a need to identify patients with similar characteristics, prognosis or treatment, defining the so-called phenotype, but also to mark specific differences within each phenotype, defining the endotypes. : Biomarkers are very useful to study respiratory phenotypes and endotypes. Metabolomics, one of the recently introduced “omics”, is becoming a leading technique for biomarker discovery. For the airways, metabolomics appears to be well suited as the respiratory tract offers a natural matrix, the Exhaled Breath Condensate (EBC), in which several biomarkers can be measured. In this review, we will discuss the main methodological issues related to the application of Nuclear Magnetic Resonance (NMR) spectroscopy and Mass Spectrometry (MS) to EBC metabolomics for investigating respiratory diseases.

scholarly journals Biomarkers for Gastroesophageal Reflux in Respiratory Diseases

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Össur Ingi Emilsson ◽  
Þórarinn Gíslason ◽  
Anna-Carin Olin ◽  
Christer Janson ◽  
Ísleifur Ólafsson
Keyword(s):  
Gastroesophageal Reflux ◽  
Respiratory Diseases ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Respiratory Illnesses ◽  
Transplant Patients ◽  
Exhaled Air ◽  
Different Types ◽  
Biochemical Profiles ◽  
Breath Condensate

Gastroesophageal reflux (GER) is commonly associated with respiratory symptoms, either through a vagal bronchoconstrictive reflex or through microaspiration of gastric contents. No diagnostic test is available, however, to diagnose when respiratory illnesses are caused by GER and when not, but research in this field has been moving forward. Various biomarkers in different types of biosamples have been studied in this context. The aim of this review is to summarize the present knowledge in this field. GER patients with respiratory diseases seem to have a different biochemical profile from similar patients without GER. Inflammatory biomarkers differ in asthmatics based on GER status, tachykinins are elevated in patients with GER-related cough, and bile acids are elevated in lung transplant patients with GER. However, studies on these biomarkers are often limited by their small size, methods of analysis, and case selections. The two pathogenesis mechanisms are associated with different respiratory illnesses and biochemical profiles. A reliable test to identify GER-induced respiratory disorders needs to be developed. Bronchoalveolar lavage is too invasive to be of use in most patients. Exhaled breath condensate samples need further evaluation and standardization. The newly developed particles in exhaled air measurements remain to be studied further.

Sign in / Sign up

Export Citation Format

Share Document